SELL (trim 25-40%, retain 50-75% of benchmark weight, stop at 204, re-evaluate at Q3 earnings)

• Q2 FCF collapsed from 4.78 billion to 2.21 billion, but 1.35 billion was due to negative working capital change (receivables built up, deferred revenue timing), making it a timing artifact rather than structural collapse
• TTM free cash flow is 12.05 billion with 1.9x dividend coverage, suggesting the value trap hasn't sprung yet
• Stock is in confirmed downtrend trading below all major moving averages: 200 SMA falling from 270 to 253 over three months, 50 SMA and 10 EMA both sloping lower
• Price hugging lower Bollinger Band at 216.56 with overhead resistance stacked at 227, 231, 233, 250, and 254
• Sep 30 selloff on positive news represents price-action divergence the market is discounting IBM downward
• 16.7x forward P/E is generous, not cheap, given negative EPS growth, declining FCF sequentially, and higher-for-longer rate regime where multiples compress
• 3.07 percent dividend yield with 0.708 beta provides genuine yield-substitution value for income-oriented accounts in 97 percent no-cuts environment
• Trim preserves optionality: if Q3 earnings prove bearish thesis wrong, firm still has meaningful exposure; if Q3 confirms deterioration, retained position damage is contained
• Stop loss at 204 sits below July 22 low of 204.30 and lower Bollinger Band at 216.56, providing roughly 13 dollars of downside (about 2x ATR)
• Palantir pitch at 73-times-sales after 60 percent three-month rally represents performance-chasing that contradicts conservative risk management principles

→ vs aggressive: Full exit or tactical short introduces new asymmetric risks the firm doesn't have; shorts have unlimited downside, and a 0.708 beta name near lower Bollinger Band support with a 3 percent dividend floor and income-substitution buyers is not the stock to short

→ vs aggressive: FCF deterioration overstated; Q2's 2.21 billion was depressed by timing artifact (1.35 billion working capital change), not structural collapse; TTM FCF remains 12.05 billion

→ vs aggressive: Dell, Palantir, Arista pitch is performance-chasing; selling a low-beta 3 percent yielder near multi-year support to buy 73-times-sales Palantir after a 60 percent three-month run is trend-following, not risk management

→ vs neutral: Position is in confirmed downtrend below every major moving average with deteriorating technical structure; constructive narrative is insufficient reason to hold a position in this technical state

→ vs neutral: Own report flags Sep 30 selloff on positive news as distribution signal; this price-action divergence must be respected, not dismissed with 'wait for Q3 earnings' justification

→ vs neutral: 16.7x forward P/E framing as 'not expensive' is anchoring to trailing valuation in a regime demanding forward-looking discipline; in higher-for-longer environment with 30-year Treasuries at highest since 2002, multiples on names with negative EPS growth and declining FCF tend to compress, not expand

→ vs neutral: Institutional confidence rated 'medium' is the analyst's own data confirming the bullish case isn't locked in; doing nothing leaves the firm fully exposed to risks already manifesting in price

Trim 35-40% of position at $227, retain 50-60% of benchmark weight; stop at $204; sell 1/3 at $222, 1/3 at $226-$228, hold final 1/3 for $233 test or Q3 earnings; halve remaining position if price closes below lower Bollinger Band on rising volume

• Trim 35-40% of position at $227 (higher end of trader's proposed 25-40% range)
• Retain 50-60% of benchmark weight rather than fully exiting
• Stop at $204 (below July 22 low and ~2 ATR from lower Bollinger Band)
• Staged execution: sell 1/3 at $222, 1/3 at $226-$228, hold final 1/3 for $233 test or Q3 earnings
• Add tactical rule: halve remaining position if price closes below lower Bollinger Band ($216) on rising volume
• 29 consecutive years of dividend growth
• TTM FCF coverage at 1.4x on most recent quarter run-rate
• One weak quarter does not constitute structural deterioration without Q3 confirmation
• Full MA stack bearish, negative EPS print, 54% sequential FCF decline
• Yield-substitution value genuine in 97% no-cuts environment
• Overhead resistance at $227, $230, $233, and 50%-54% retracement zone

→ vs aggressive: One weak quarter is insufficient to declare structural FCF deterioration; TTM FCF still $12B; FCF yield becomes a trap only with consecutive quarters of coverage failure; Q3 must print another sub-$3B quarter before thesis becomes evidence

→ vs conservative: Anchoring to TTM FCF ignores the 1.4x coverage on most recent quarter run-rate, which is a legitimate warning signal that was glossed over; 50-75% weight in a stock printing negative EPS, 54% sequential FCF decline, and below all major MAs is not proportional to the evidence